“Dupilumab in Moderate-to-Severe Atopic Dermatitis: Pooled Efficacy Results from Two Identically Designed Randomized Phase 3 Trials (SOLO 1 & 2)” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s38. doi:10.25251/skin.1.supp.37.